Search results
Ivonescimab shows promise in NSCLC Phase III trial By Investing.com
Investing.com· 7 days agoSummit Therapeutics Inc. (NASDAQ: NASDAQ:SMMT) announced that its Phase III clinical trial,...
Immunotherapy drug may keep colon cancer patients cancer-free after surgery
United Press International via Yahoo News· 3 days agoDoctors in Britain say that an immunotherapy drug, given before surgery, can help many more colon...
Citi sees potential in Summit Therapeutics's ivonescimab, raises stock PT By Investing.com
Investing.com· 6 days agoThe trial, named HARMONi-2, is currently taking place exclusively in China and has shown that...
Novel Bispecific in EGFR-Mutant Lung Cancer Boosts PFS After Targeted Agents
MedPage Today· 5 days agoChina-based trial may present a hurdle to FDA approval, however
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 3 days agoResearchers from NYU Langone Health's Perlmutter Cancer Center are presenting their latest findings and research at the 2024 American Society of Clinical Oncology (ASCO) Annual Conference, held ...
Experimental therapy shows promise in pancreatic cancer clinical trial
Medical Xpress· 5 days agoBXCL701, made by BioXcel Therapeutics, is an oral drug called an immune activator. It acts by...
Lack of insurance keeps many Americans from best cancer meds
Medical Xpress· 3 days agoThe study was led by ACS researcher Dr. Jingxuan Zhao. ICIs include such blockbuster cancer...
...Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained...
Digital Journal· 3 days agoAt a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis ...
Fewer Suicides in Cancer Patients; Circadian Rhythm Boost; HIV Vaccine for Cancer?
MedPage Today· 6 days agoNews, features, and commentary about cancer-related issues
Sarcoma immunotherapy clinical trial reduces risk of relapse by 43%
Medical Xpress· 2 days agoFor the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare...